REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy.


Perol M., Ciuleanu T., Arrieta O., Prabhash K., Syrigos K. N. , Goksel T. , ...Daha Fazla

JOURNAL OF CLINICAL ONCOLOGY, cilt.32, 2014 (SCI İndekslerine Giren Dergi) identifier

  • Cilt numarası: 32 Konu: 18
  • Basım Tarihi: 2014
  • Dergi Adı: JOURNAL OF CLINICAL ONCOLOGY